NCT02107391View on ClinicalTrials.gov

Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

June 30, 2016

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

Dendritic Cells DCVAC/PCa

Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy

DRUG

Leuprolide acetate

Standard of Care Hormone Therapy as an Active Comparator

DRUG

Goserelin Acetate

Standard of Care Hormone Therapy as an Active Comparator

Trial Locations (9)

Unknown

Jablonec nad Nisou

Jihlava

Liberec

Mníšek pod Brdy

Olomouc

Pilsen

Prague

Ústí nad Labem

Zlín

All Listed Sponsors
lead

SOTIO a.s.

INDUSTRY

NCT02107391 - Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter